AR055303A1 - Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento - Google Patents
Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamentoInfo
- Publication number
- AR055303A1 AR055303A1 ARP060100188A ARP060100188A AR055303A1 AR 055303 A1 AR055303 A1 AR 055303A1 AR P060100188 A ARP060100188 A AR P060100188A AR P060100188 A ARP060100188 A AR P060100188A AR 055303 A1 AR055303 A1 AR 055303A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- ring
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a triazoles sustituidos de formula (1), a procedimientos para su preparacion, a composiciones que contienen dicho compuestos y usos del compuesto en la preparacion de un medicamento. Estos inhibidores tienen utilidad en diversas áreas terapéuticas incluyendo disfuncion sexual. Reivindicacion 1: Un compuesto de formula (1), en la que: m está en el intervalo de 1 a 4 y n es 1 o 2 con la condicion de que m + n está en el intervalo de 2 a 5; X se selecciona entre O, NH, N-alquiloC1-6, NC(O)-alquiloC1-6, N(SO2-alquiloC1-6), S y SO2; R1 se selecciona entre: i) un anillo fenilo o naftilo; ii) un anillo heterocíclico aromático de 5 a 6 miembros que contiene 1 a 3 heteroátomos seleccionados independientemente entre N, O y S y N-oxidos de los mismos; iii) un anillo heterocíclico, aromático, bicíclico de 9 a 10 miembros que contiene de 1 a 4 heteroátomos seleccionados independientemente entre N, O y S N-oxidos de los mismos; y iv) 2-piridonilo; cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halo, alquilo C1-6, alcoxi C1-6, alcoxiC1-6-alquiloC1-6, ciano, CF3, NH-alquiloC1-6, N-(alquiloC1-6)2, CO-alquiloC1-6, C(O)O-alquiloC1-6, C(O)NH- alquiloC1-6, C(O)N-(alquiloC1-6)2, C(O)OH y C(O)NH2; R2 se selecciona entre: i) H e hidroxi; ii) alquilo C1-6, que está opcionalmente sustituido con O-alquiloC1-6 o fenilo; iii) O-alquiloC1-6, que está opcionalmente sustituido con O-alquiloC1-6; iv) NH-alquiloC1-6, estando dicho grupo alquilo opcionalmente sustituido con O-alquiloC1-6; v) N-(alquiloC1-6)2, estando uno o ambos de dichos grupos alquilo opcionalmente sustituidos con O-alquiloC1-6; vi) un heterociclo de 5 a 8 miembros saturado o parcialmente saturado y N-enlazado que contiene de 1 a 3 heteroátomos, cada uno seleccionado independientemente entre N, O y S, donde al menos un heteroátomo es N y donde dicho anillo puede incorporar opcionalmente uno o dos grupos carbonilo; estando dicho anillo opcionalmente sustituido con uno o más grupos seleccionados entre CN, halo, alquilo C1-6, O-alquiloC1-6, NH-alquiloC1-6, N-(alquiloC1-6)2, C(O)-alquiloC1-6, C(O)O-alquiloC1-6, C(O)NH-alquiloC1-6, C(O)N-(alquiloC1-6)2, C(O)OH, C(O)NH2 y C(O)OCH2Ph; y vii) un heterociclo aromático de 5 a 7 miembros N-enlazado que contiene de 1 a 3 heteroátomos, cada uno seleccionado independientemente entre N, O y S, donde al menos un heteroátomo es N; estando dicho anillo opcionalmente sustituido con uno o más grupos seleccionado entre CN, halo, alquilo C1-6, O-alquiloC1-6, NH-alquiloC1-6, N-(alquiloC1-6)2, C(O)-alquiloC1-6, C(O)O-alquiloC1-6, C(O)NH-alquiloC1-6, C(O)N-(alquiloC1-6)2, C(O)OH, C(O)NH2 y C(O)OCH2Ph; y R3 se selecciona entre H, alquilo C1-6 y alcoxiC1-6-alcoxiC1-6; cada uno de R4, R5, R6 y R7 se selecciona independientemente entre H, halo, hidroxi, CN, alquilo C1-6, NH-alquiloC1-6, N-(alquiloC1-6)2 y O-alquiloC1-6; R8 se selecciona entre H, alquilo C1- 6, alcoxiC1-6-alquiloC1-6, CH2OH, CH2NH2, CHNH-alquiloC1-6, CH2N-(alquiloC1-6)2, CN, C(O)NH2, C(O)NH-alquiloC1-6 y C(O)N-(alquiloC1-6)2; un tautomero del mismo o una sal, solvato o polimorfo farmacéuticamente aceptable de dicho compuesto o tautomero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0501190.3A GB0501190D0 (en) | 2005-01-20 | 2005-01-20 | Novel pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055303A1 true AR055303A1 (es) | 2007-08-15 |
Family
ID=34259404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100188A AR055303A1 (es) | 2005-01-20 | 2006-01-18 | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US7557131B2 (es) |
| EP (1) | EP1841758B1 (es) |
| JP (1) | JP4124805B1 (es) |
| KR (1) | KR100936854B1 (es) |
| CN (1) | CN101107243B (es) |
| AP (1) | AP2007004047A0 (es) |
| AR (1) | AR055303A1 (es) |
| AT (1) | ATE449091T1 (es) |
| AU (1) | AU2006207300B2 (es) |
| BR (1) | BRPI0606463A2 (es) |
| CA (1) | CA2595569C (es) |
| CR (1) | CR9219A (es) |
| DE (1) | DE602006010508D1 (es) |
| DK (1) | DK1841758T3 (es) |
| DO (1) | DOP2006000014A (es) |
| EA (1) | EA200701328A1 (es) |
| ES (1) | ES2334517T3 (es) |
| GB (1) | GB0501190D0 (es) |
| GT (1) | GT200600024A (es) |
| IL (1) | IL184148A (es) |
| MA (1) | MA29160B1 (es) |
| MX (1) | MX2007008757A (es) |
| NL (1) | NL1030961C2 (es) |
| NO (1) | NO338420B1 (es) |
| PA (1) | PA8660401A1 (es) |
| PE (1) | PE20060875A1 (es) |
| TN (1) | TNSN07275A1 (es) |
| TW (1) | TW200637847A (es) |
| UY (1) | UY29339A1 (es) |
| WO (1) | WO2006077496A1 (es) |
| ZA (1) | ZA200705718B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06284516A (ja) * | 1993-03-31 | 1994-10-07 | Mitsubishi Electric Corp | 電気車制御装置 |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| EP1902051A1 (en) * | 2005-06-09 | 2008-03-26 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| US20090170828A1 (en) * | 2006-06-12 | 2009-07-02 | Elise Isabel | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase |
| EP2032570A4 (en) * | 2006-06-13 | 2010-10-27 | Merck Frosst Canada Ltd | AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| JP2010527915A (ja) * | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ，インコーポレイテッド | 多重環化合物及びその用途 |
| MX2010007660A (es) * | 2008-01-31 | 2010-08-10 | Sanofi Aventis | Indol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos. |
| WO2009095162A1 (en) | 2008-01-31 | 2009-08-06 | Sanofi-Aventis | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| PL2872487T3 (pl) * | 2012-07-16 | 2017-09-29 | Fibrogen, Inc. | Sposób wytwarzania związków izochinolinowych |
| US10570146B2 (en) * | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| FI3541784T3 (fi) | 2016-11-18 | 2023-10-02 | Integrative Res Laboratories Sweden Ab | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina |
| CN108884071B (zh) * | 2016-12-21 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用 |
| MX2019007360A (es) * | 2016-12-28 | 2019-08-16 | Jiangsu Hengrui Medicine Co | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. |
| CN111094272B (zh) * | 2018-06-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种otr抑制剂的可药用盐、晶型及制备方法 |
| CN111094273B (zh) * | 2018-06-20 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 催产素受体抑制剂的晶型及其制备方法 |
| CN111902406B (zh) * | 2018-06-27 | 2022-11-18 | 江苏恒瑞医药股份有限公司 | 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法 |
| CN113004250B (zh) * | 2019-12-19 | 2022-07-26 | 上海森辉医药有限公司 | 一种制备取代的三唑衍生物的方法 |
| CN113582818B (zh) * | 2021-08-30 | 2023-08-01 | 上海日异生物科技有限公司 | 一种3-卤-2-烷基苯酚的合成方法 |
| MX2024010096A (es) * | 2022-02-16 | 2024-08-28 | Duke Street Bio Ltd | Compuesto farmaceutico. |
| CN114805161B (zh) * | 2022-06-14 | 2023-08-25 | 南通华祥医药科技有限公司 | 一种3-氟丫丁啶盐酸盐的制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
| US5053411A (en) | 1989-04-20 | 1991-10-01 | Anaquest, Inc. | N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds |
| DE4124942A1 (de) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JP2000509371A (ja) | 1996-04-03 | 2000-07-25 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| WO1997036585A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0891356A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| EP1003374A1 (en) | 1996-12-30 | 2000-05-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ES2258300T3 (es) | 1997-12-16 | 2006-08-16 | Pfizer Products Inc. | Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia. |
| BR0012697A (pt) | 1999-07-23 | 2002-04-09 | Shionogi & Co | Inibidores da diferenciação de th2 |
| WO2001029011A2 (en) | 1999-10-15 | 2001-04-26 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| AU779426B2 (en) | 1999-11-15 | 2005-01-27 | Janssen Pharmaceutica N.V. | Triazoles as farnesyl transferase inhibitors |
| WO2001076582A1 (fr) | 2000-04-05 | 2001-10-18 | Shionogi & Co., Ltd. | Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci |
| PL359340A1 (en) | 2000-05-19 | 2004-08-23 | Triazole derivatives | |
| US20030216385A1 (en) | 2000-05-19 | 2003-11-20 | Takahiko Tobe | Triazole derivatives |
| CA2462645A1 (en) | 2001-10-03 | 2003-11-13 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0208579D0 (en) | 2002-04-13 | 2002-05-22 | British Biotech Pharm | Antibacterial agents |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| JP2007505888A (ja) * | 2003-09-22 | 2007-03-15 | ファイザー インコーポレイテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| GEP20084571B (en) | 2003-12-22 | 2008-12-25 | Pfizer | Triazole derivatives as vasopressin antagonists |
| WO2005082866A2 (en) * | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| EP1742932A1 (en) | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
-
2005
- 2005-01-11 AP AP2007004047A patent/AP2007004047A0/xx unknown
- 2005-01-20 GB GBGB0501190.3A patent/GB0501190D0/en not_active Ceased
-
2006
- 2006-01-11 MX MX2007008757A patent/MX2007008757A/es active IP Right Grant
- 2006-01-11 CA CA2595569A patent/CA2595569C/en not_active Expired - Lifetime
- 2006-01-11 BR BRPI0606463-9A patent/BRPI0606463A2/pt not_active IP Right Cessation
- 2006-01-11 KR KR1020077016553A patent/KR100936854B1/ko not_active Expired - Fee Related
- 2006-01-11 EP EP06710261A patent/EP1841758B1/en not_active Expired - Lifetime
- 2006-01-11 AT AT06710261T patent/ATE449091T1/de not_active IP Right Cessation
- 2006-01-11 JP JP2007551766A patent/JP4124805B1/ja not_active Expired - Fee Related
- 2006-01-11 WO PCT/IB2006/000118 patent/WO2006077496A1/en not_active Ceased
- 2006-01-11 ES ES06710261T patent/ES2334517T3/es not_active Expired - Lifetime
- 2006-01-11 DE DE602006010508T patent/DE602006010508D1/de not_active Expired - Lifetime
- 2006-01-11 EA EA200701328A patent/EA200701328A1/ru unknown
- 2006-01-11 CN CN2006800028617A patent/CN101107243B/zh not_active Expired - Fee Related
- 2006-01-11 DK DK06710261.6T patent/DK1841758T3/da active
- 2006-01-11 AU AU2006207300A patent/AU2006207300B2/en not_active Ceased
- 2006-01-17 PE PE2006000072A patent/PE20060875A1/es not_active Application Discontinuation
- 2006-01-17 DO DO2006000014A patent/DOP2006000014A/es unknown
- 2006-01-18 UY UY29339A patent/UY29339A1/es active IP Right Grant
- 2006-01-18 AR ARP060100188A patent/AR055303A1/es unknown
- 2006-01-19 GT GT200600024A patent/GT200600024A/es unknown
- 2006-01-19 TW TW095102071A patent/TW200637847A/zh unknown
- 2006-01-19 NL NL1030961A patent/NL1030961C2/nl not_active IP Right Cessation
- 2006-01-20 US US11/335,940 patent/US7557131B2/en active Active
- 2006-01-20 PA PA20068660401A patent/PA8660401A1/es unknown
-
2007
- 2007-06-21 IL IL184148A patent/IL184148A/en active IP Right Grant
- 2007-07-02 CR CR9219A patent/CR9219A/es not_active Application Discontinuation
- 2007-07-11 ZA ZA200705718A patent/ZA200705718B/xx unknown
- 2007-07-19 TN TNP2007000275A patent/TNSN07275A1/fr unknown
- 2007-07-20 MA MA30089A patent/MA29160B1/fr unknown
- 2007-08-14 NO NO20074177A patent/NO338420B1/no unknown
-
2009
- 2009-05-15 US US12/466,785 patent/US8207198B2/en not_active Expired - Fee Related
-
2012
- 2012-05-23 US US13/478,384 patent/US9023872B2/en not_active Expired - Lifetime
-
2015
- 2015-04-20 US US14/691,319 patent/US9394278B2/en not_active Expired - Fee Related
-
2016
- 2016-06-28 US US15/195,480 patent/US10150752B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| CR20110616A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| BRPI0518651A2 (pt) | composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR037736A1 (es) | Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r) | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR069545A1 (es) | Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
| AR050617A1 (es) | Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas | |
| ECSP088257A (es) | Derivados de amida | |
| DE60214401D1 (de) | Hetero-bicyclische crf antagonisten | |
| AR071619A1 (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |